摘要
目的 研究美洛昔康治疗类风湿关节炎的疗效和安全性。方法 美洛昔康组 19例 ,口服美洛昔康 15mg ,每天1次 ;萘丁美酮组 2 1例 ,口服萘丁美酮 10 0 0mg,每天 1次 ,疗程 4周 ,采用随机、双盲、平行的比较研究。结果 美洛昔康总有效率为 73 6 8% ;萘丁美酮为 6 1 90 % (P >0 0 5 )。两药均能显著改善患者的症状和体征 ,降低血沉。不良反应发生率 :美洛昔康为 10 5 3 % ;萘丁美酮为 2 8 5 7%。统计分析两药的耐受性差异无显著性。不良反应均为轻度消化道症状 ,仅个别需对症处理。结论 美洛昔康和萘丁美酮双盲治疗类风湿关节炎的疗效相似 。
Objective To evaluate the efficacy and safety of meloxicam and nabumetone in the treatment of patients with rheumatoid arthritis. Methods Double blind, randomized, controlled clinical trial of meloxicam versus nabumetone was performed. Forty patients (meloxicam 19 cases, nabumetone 21 cases) were given meloxicam po with 15 mg·L -1 or nabumetone 1 000 mg·L -1 ,respectively, for 4 weeks. Results Meloxicam and nabumetone could improve the symptoms and signs of rheumatoid arthritis, decrease ESR. The total efficacy rates of meloxicam were 73 68%;and the nabumetone were 61 90%, after 4 weeks of treatment. The incidence of adverse drug reaction of meloxicam were 10 53%; nabumetone were 28 57%. Main adverse reactions were symptoms of gastrointestinal tract. All adverse drug reaction of both drugs were mild and none ceased treatment. Conclusion Meloxicam has a good efficacy and tolerance in the treatment of rheumatoid arthritis.
出处
《安徽医科大学学报》
CAS
2001年第4期290-292,共3页
Acta Universitatis Medicinalis Anhui
